https://orcid.org/0000-0002-1809-184X
References
- Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–2481.
- Gray M, Jani A. Promoting triple value healthcare in countries with universal healthcare. Healthc Pap. 2016;15(3):42–48.
- Ponzetti C, Canciani M, Farina M et al. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227–233.
- [cited 2019 Oct]. Available from: http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_Product_Information/human/000165/WC500025821.pdf
- [cited 2019 Oct]. Available from: http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_Product_Information/human/000278/WC500074922.pdf
- Jackisch C, Kim SB, Semiglazov V, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015;26:320–325.
- Pivot X, Gligorov J, Müller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962–970.
- Davies A, Merli F, Mihaljevic B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017 Jun;4(6):e272–e282.
- Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017 Apr 1;28(4):836–842.
- Job Salary Outlook. 2015. [cited 2019 Oct]. Available from: https://www.jobpricing.it/blog/panorama-retribuzioni-italia-2015/
- North RT, Harvey VJ, Cox LC, et al. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. Clinicoecon Outcomes Res. 2015;7:423–430.
- Olofsson S, Norrlid H, Karlsson E, et al. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast. 2016 Oct;29:140–146.
- Tjalma WAA, Van den Mooter T, Mertens T, et al. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2- positive breast cancer: a time, motion and cost assessment study in a lean operating day care oncology unit. Europ J Obstet Gynec Reprod Biol. 2018;221:46–51.
- O’Brien GL, O’Mahony C, Cooke K, et al. Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland. Clin Breast Cancer. 2019 Jun;19(3):e440–e451.
- Pivot X, Gligorov J, Müller V, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25:1979–1987.